Results for CTL/CD8+ T-Cell Epitope Variants
|
QGTVSFSFPQITLWQRPL
|
Pol(49-66)
|
human epitope
|
-----lSFPQITLW----
|
Pol(49-66)
|
escape documented in this paper; observed variant
|
SFPQITLWQRPLVT
|
Pol(55-68)
|
B51, B52 human epitope
|
QITLWQRPLVSIKVGGQI
|
Pol(58-75)
|
C*08:01 human epitope
|
QITLWQRPLVSIKVGGQI
|
Pol(58-75)
|
C*12, C*14 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
A*68:02, A*74:01, A19 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
A2 human epitope
|
ITLWQRPiV
|
Pol(59-67)
|
observed variant
|
ITLWQRPfV
|
Pol(59-67)
|
observed variant
|
ITLWQRPLV
|
Pol(59-67)
|
A2 transgenic mouse epitope
|
ITLWQRPLV
|
Pol(59-67)
|
A28 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
A28 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
A28 supertype human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
A68 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
A*68:02 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
A*68:02 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
A74 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
A*74:01 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
A*74:01 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
B*35:02, B*35:03, B*53:01 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
B*40 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
C*04 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
C*15 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
C*17 human epitope
|
ITLWQRPLV
|
Pol(59-67)
|
human epitope
|
ITLWQRPIV
|
Pol(59-67)
|
human epitope
|
ITLWQRPlV
|
Pol(59-67)
|
observed variant
|
ITLWQRPLV
|
Pol(59-67)
|
human epitope
|
ITLWQRPiV
|
Pol(59-67)
|
drug induced; observed variant
|
TLWQRPLVTIR
|
Pol(60-70)
|
A*33:03 human epitope
|
LWQRPLVTIKIGGQLKEA
|
Pol(61-78)
|
human epitope
|
WQRPLVTI
|
Pol(62-69)
|
B*52:01 human epitope
|
WQRPLViI
|
Pol(62-69)
|
escape documented in this paper; observed variant
|
WQRPLVaI
|
Pol(62-69)
|
escape documented in this paper; observed variant
|
QRPLVTIKI
|
Pol(63-71)
|
A*01:01 human epitope
|
QRPiVTIKI
|
Pol(63-71)
|
drug induced; susceptible form
|
QRPLVTVKIG
|
Pol(63-72)
|
B51 human epitope
|
QRPiVTVKIG
|
Pol(63-72)
|
drug induced; escape documented in this paper
|
QRPLVTVrIG
|
Pol(63-72)
|
HLA association; drug induced
|
RPLVTIKI
|
Pol(64-71)
|
B*51 human epitope
|
RPLVTIKI
|
Pol(64-71)
|
B*51 human epitope
|
PLVTIKIGGQL
|
Pol(65-75)
|
B*67:01 human epitope
|
VTIKIGGQLK
|
Pol(67-76)
|
A*03:01 human epitope
|
VTIKIGGQLK
|
Pol(67-76)
|
A*11:01 human, humanized mouse, mouse epitope
|
VaIKIGGQLK
|
Pol(67-76)
|
non-susceptible form
|
VTIKIGGQLr
|
Pol(67-76)
|
susceptible form
|
VTvKIGGQLK
|
Pol(67-76)
|
susceptible form
|
VTIrIGGQLK
|
Pol(67-76)
|
susceptible form
|
VTIKvGGQLK
|
Pol(67-76)
|
susceptible form
|
VTIKIeGQLK
|
Pol(67-76)
|
non-susceptible form
|
VTIKIGGQiK
|
Pol(67-76)
|
susceptible form
|
VTvKIGGQLr
|
Pol(67-76)
|
susceptible form
|
VTvKIGGeLK
|
Pol(67-76)
|
non-susceptible form
|
VTvKIeGQLK
|
Pol(67-76)
|
non-susceptible form
|
VTvKvGGQLK
|
Pol(67-76)
|
susceptible form
|
VTvrIGGQLK
|
Pol(67-76)
|
susceptible form
|
VTIrIGGQLr
|
Pol(67-76)
|
susceptible form
|
VTIrvGGQLK
|
Pol(67-76)
|
susceptible form
|
VaIKIGGQiK
|
Pol(67-76)
|
susceptible form
|
VnIKvGGQLK
|
Pol(67-76)
|
non-susceptible form
|
VTIKIGGQir
|
Pol(67-76)
|
non-susceptible form
|
VTIKlGGQir
|
Pol(67-76)
|
susceptible form
|
VTvKIeGQLr
|
Pol(67-76)
|
non-susceptible form
|
VTvKvGGQLr
|
Pol(67-76)
|
susceptible form
|
VTIrvGGQLr
|
Pol(67-76)
|
susceptible form
|
VsIKvGGQiK
|
Pol(67-76)
|
susceptible form
|
VTvrvGGQLK
|
Pol(67-76)
|
susceptible form
|
VTIrvaGQvK
|
Pol(67-76)
|
non-susceptible form
|
VsIrvGGQtK
|
Pol(67-76)
|
non-susceptible form
|
VsIrvGGQiK
|
Pol(67-76)
|
non-susceptible form
|
VsIKvGGQir
|
Pol(67-76)
|
non-susceptible form
|
VTvrIGGmqK
|
Pol(67-76)
|
non-susceptible form
|
VsIrvGGQtr
|
Pol(67-76)
|
non-susceptible form
|
iTvKIGkevr
|
Pol(67-76)
|
non-susceptible form
|
VTIKIGGQLK
|
Pol(67-76)
|
A3 human epitope
|
VTILIGGQLK
|
Pol(67-76)
|
A3 supertype human epitope
|
VTIKIGGQLK
|
Pol(67-76)
|
A3 supertype human, mouse epitope
|
TIKIGGQLK
|
Pol(68-76)
|
A3 supertype human epitope
|